Document Classification

Section Type: RESULTS

Text: In the clinical trial, as compared with placebo, 10 weeks of treatment with etanercept was associated with a significant increase in the concentration of methacholine required to provoke a 20 percent decrease in the forced expiratory volume in one second (FEV1) (mean difference in doubling concentration changes between etanercept and placebo, 3. 5 ; 95 percent confidence interval, 0. 07 to 7. 0 ; P = 0. 05), an improvement in the asthma-related quality-of-life score (by 0. 85 point ; 95 percent confidence interval, 0. 16 to 1. 54 on a 7-point scale ; P = 0. 02), and a 0. 32-liter increase in post-bronchodilator FEV1 (95 percent confidence interval, 0. 08 to 0. 55 ; P = 0. 01).